Amicus Therapeutics, Inc.FOLDNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank29
3Y CAGR-14.2%
5Y CAGR-21.1%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-14.2%/yr
vs -14.9%/yr prior
5Y CAGR
-21.1%/yr
Recent acceleration
Acceleration
+0.6pp
Accelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 7.35 | +25.3% |
| 2024 | 5.86 | -46.6% |
| 2023 | 10.98 | -5.6% |
| 2022 | 11.64 | +6.8% |
| 2021 | 10.90 | -54.5% |
| 2020 | 23.98 | +81.4% |
| 2019 | 13.22 | -40.3% |
| 2018 | 22.16 | -64.8% |
| 2017 | 62.88 | -50.9% |
| 2016 | 128.16 | - |